Clinical medicine profile
Oestrogen / Medroxyprogesterone (Conjugated)
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Venous or arterial thrombo-embolic
- Prodromi of thrombosis such as transient ischaemic attack and angina pectoris
- diabetes mellitus with vascular involvement
- severe risk factors for venous or arterial thrombosis
- severe hepatic disease
Precautions
- Obtain allergy and medication history.
- Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
- Use the lowest effective dose for the shortest appropriate duration.
- Monitor for expected class adverse effects.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Menorrhagia: 2.5-10 mg daily X 5/7 to 10/7 on days 16-21 of the menstrual cycle to be repeated for 2 cycles. Mild to moderate endometriosis:10 mg TID. Breast cancer: 0.4-1.5 g per day [max: 2g daily. Palliation of endometrial and renal carcinoma: 200-600 mg per day. Palliation of prostatic carcinoma: 100-600 mg per day. Secondary amenorrhoea: 2.5-10 mg per day for 5/7 to 10/7. Repeat for 3 cycles.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Menopausal symptoms
Adverse effects
- Tenderness, pain and secretion of breasts
- headache
- changes in sexual drive, depressive moods, contact lens intolerance, GI disturbances, changes in vaginal secretion, skin reactions, fluid retention, changes in body weight, hypersensitivity reactions
Drug interactions
Open multi-drug checker ↗- Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
- Document allergy status and key interactions.
Mechanism & disposition
See under estrogen and progesterone respectively Mechanism is agent-specific.
Read complete mechanism
See under estrogen and progesterone respectively Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.